EDGAR·FLOW

SELLAS Life Sciences Group, Inc. — Form 8-K

Filed November 20, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 68/100
What the filing says
SELLAS Life Sciences priced an underwritten public offering of 11,538,462 shares at $13.00 per share on November 18, 2026, generating gross proceeds of $150.0 million. The company granted underwriters a 30-day option to purchase an additional 1,730,769 shares at the same price. J.P. Morgan and TD Securities are lead underwriters; closing expected November 20, 2026.
Why this rating

Major capital raise ($150M gross) is 68% of company's market cap; materially strengthens balance sheet and extends runway for late-stage oncology programs.

View original filing on SEC.gov ↗ SLS · stock on Yahoo Finance ↗

See more from November 20, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.